AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 52 min read$ALMS

Pangali Sanam sold $36K of ALMS

Pangali Sanam (Chief Legal Officer) sold 1,364 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Pangali Sanam
Published Aug 5, 2026, 10:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALMS
Neutral
low confidence
Mentioned
$ALMS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale size, price, and post-transaction holdings, with no 10b5-1 plan indicated.

02

Market read

Traders may note insider selling for sentiment, but there is no new guidance, contract, or regulatory development in the text.

03

What to watch

The article does not state whether the sale was part of broader planned selling, nor does it provide context on total holdings, compensation, or prior sale patterns.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-08-05 after-hours; reflects sale executed 2026-08-03.

Background

The filing is an SEC Form 4 insider transaction for ALUMIS INC. (ALMS) by its Chief Legal Officer, Pangali Sanam.

Company-level read

Ticker impact

$ALMSNeutralLow confidence
Context

ALMS insider Pangali Sanam sold 1,364 shares on 2026-08-03 at $26.3700, disclosing $35,968.68 in proceeds.

Expected impact

Likely limited near-term impact; any effect would be short-lived unless paired with other company-specific news.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction details but no new operational or financial guidance.

Market effects

Sector

No clear sector read-through from a single insider sale without additional company or industry disclosures.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be for personal liquidity or tax planning and does not necessarily signal reduced confidence, especially without any accompanying negative company news.

Key entities

  • issuer
    ALUMIS INC.

    Company whose insider transaction is disclosed on Form 4.

  • insider
    Pangali Sanam

    Chief Legal Officer who sold 1,364 shares of ALMS.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALMS insider trading history →

Related articles

SEP 1
$ALMSMedAI 8/10

Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.

rttnews.com2 min
SEP 1
$ALMSHighAI 8/10

Why is Alumis stock collapsing today?

Alumis stock fell 54.2% in pre-market trading after its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus missed primary and secondary endpoints. A subgroup of patients showed positive responses, but the overall trial population was under-represented. The company plans to discuss a Phase 3 program with regulators. The Nasdaq, S&P 500, and Dow Jones also declined, exacerbating the sell-off.

investing.com2 min
SEP 1
$ALMSHighAI 8/10

Alumis stock tumbles 55% after lupus drug trial misses goals

Alumis Inc. (ALMS) shares dropped 55% after its Phase 2b LUMUS trial for envudeucitinib in lupus failed primary and secondary endpoints. The trial enrolled 408 patients but showed improvements only in a subgroup with high interferon gene signature (IFNGS-high). The drug was well-tolerated, and the company plans to discuss Phase 3 development for this subgroup with regulators. Alumis remains on track to submit a New Drug Application for psoriasis in Q4 2026.

investing.com2 min
SEP 1
$ALMSLowAI 8/10

Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust responses. The company plans to discuss Phase 3 development with regulators. Envudeucitinib was well tolerated. Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psor

finanznachrichten.de2 min